BioCentury | Apr 1, 2021
Product Development

April 1 Quick Takes: BioNTech, Pfizer to seek full approval of vaccine; plus CEPI’s call and FDA’s latest batch of expanded labels

...strategy.FDA expands labels for Tyvaso, Sarclisa, Vyxeos, PraluentFDA has granted a second approval for drugs from United Therapeutics Corp....
...REGN727 (Compound #), alirocumab (Generic), Praluent (Other) Coalition for Epidemic Preparedness Innovations (CEPI) BioNTech SE Pfizer Inc. Regeneron Pharmaceuticals Inc. United Therapeutics Corp. Jazz...
BioCentury | Mar 6, 2021
Product Development

March 5 Quick Takes: A regulatory first for Actemra; plus updates from Lilly-Incyte, Kronos, Junshi, United Therapeutics, Pfizer, Sumitomo Dainippon, Arena, Oyster Point, Azura

...inhibitors; Pfizer said FDA’s latest action confers full approval on Lorbrena.End of the road for United Therapeutics’...
...Informal), MRA (Informal), Actemra (Informal) Eli Lilly and Co. Kronos Bio Inc. Shanghai Junshi Biosciences Co. Ltd. Coherus BioSciences Inc. Pfizer United Therapeutics Corp. Sumitomo...
BioCentury | Dec 31, 2020
Deals

Dec. 30 Quick Takes: COVAXX-Aurobindo and Moderna-Recipharm in COVID deals; plus United-Y-mAbs, Zai-Cullinan and Incyte-Cellenkos

...start in early 2021. Deal terms were undisclosed.United Therapeutics...
...voucher it received via Danyelza naxitamab-gqgk’s approval to United Therapeutics Corp....
...Other), Jakafi (Other) CLN-081 (TAS6417) UB-612 Incyte Corp. Cellenkos Inc. Cullinan Management Inc. United Therapeutics Corp. Y-mAbs...
BioCentury | Jun 4, 2020
Finance

Everest to fund late-stage trials with $310M mountain of fresh cash

...Pharmaceuticals Inc. (NASDAQ:ARNA); PGI2 agonist ralinepag XR for pulmonary arterial hypertension, under a deal with United Therapeutics...
BioCentury | May 14, 2020
Emerging Company Profile

Kriya emerges with $80.5M A round, three gene therapies for diabetes and obesity

...Axovant Gene Therapies Ltd. (NASDAQ:AXGT). His co-founders are Vice Chairman Roger Jeffs, former co-CEO of United Therapeutics...
BioCentury | Dec 20, 2019
Product Development

Pharma spinouts: a snapshot of where and how pharmas spin out their assets

...with a $250M series A round in 2017. Celgene, together with Sorrento Therapeutics Inc. (NASDAQ:SRNE), United Therapeutics Corp....
BioCentury | Sep 11, 2019
Company News

Sept. 11 Company Quick Takes: Glaxo to buy Sitari; plus Aimmune, Xeris, Puma and United Therapeutics

...adjuvant therapy for early stage HER2-positive breast cancer. April PDUFA date for PAH therapy Trevyent United Therapeutics Corp....
...Sackler company, Mundipharma International Ltd. (Dublin, Ireland). BioCentury Staff Avalon Ventures Sitari Pharmaceuticals Inc. GlaxoSmithKline plc Xeris Pharmaceuticals Inc. Purdue Pharma L.P. United Therapeutics Corp. Puma...
BioCentury | Jul 26, 2019
Finance

Earnings on deck

...NASDAQ:AMGN) 7/30 Post $3.59 $3.83 -6% Gilead Sciences Inc. (NASDAQ:GILD) 7/30 Post $1.72 $1.91 -10% United Therapeutics Corp....
BioCentury | Jul 1, 2019
Company News

Management Tracks: BioCryst hires its first CBO; plus ObsEva, Veracyte and more

...as CFO. He was EVP and CFO of SteadyMed Therapeutics Inc., which was acquired by United Therapeutics Corp....
BioCentury | Apr 26, 2019
Company News

Amgen, Astellas join list of biopharmas paying for alleged co-pay charity kickbacks

...Pharmaceuticals Inc. (NASDAQ:ALXN), H. Lundbeck A/S (CSE:LUN), Jazz Pharmaceuticals plc (NASDAQ:JAZZ), Pfizer Inc. (NYSE:PFE) and United Therapeutics Corp....
...Alleged Kickbacks to Co-pay Charities" ). Mary Romeo, Staff Writer Alexion Pharmaceuticals Inc. Amgen Inc. Astellas Pharma Inc. H. Lundbeck A/S United Therapeutics Corp. Actelion...
Items per page:
1 - 10 of 621
BioCentury | Apr 1, 2021
Product Development

April 1 Quick Takes: BioNTech, Pfizer to seek full approval of vaccine; plus CEPI’s call and FDA’s latest batch of expanded labels

...strategy.FDA expands labels for Tyvaso, Sarclisa, Vyxeos, PraluentFDA has granted a second approval for drugs from United Therapeutics Corp....
...REGN727 (Compound #), alirocumab (Generic), Praluent (Other) Coalition for Epidemic Preparedness Innovations (CEPI) BioNTech SE Pfizer Inc. Regeneron Pharmaceuticals Inc. United Therapeutics Corp. Jazz...
BioCentury | Mar 6, 2021
Product Development

March 5 Quick Takes: A regulatory first for Actemra; plus updates from Lilly-Incyte, Kronos, Junshi, United Therapeutics, Pfizer, Sumitomo Dainippon, Arena, Oyster Point, Azura

...inhibitors; Pfizer said FDA’s latest action confers full approval on Lorbrena.End of the road for United Therapeutics’...
...Informal), MRA (Informal), Actemra (Informal) Eli Lilly and Co. Kronos Bio Inc. Shanghai Junshi Biosciences Co. Ltd. Coherus BioSciences Inc. Pfizer United Therapeutics Corp. Sumitomo...
BioCentury | Dec 31, 2020
Deals

Dec. 30 Quick Takes: COVAXX-Aurobindo and Moderna-Recipharm in COVID deals; plus United-Y-mAbs, Zai-Cullinan and Incyte-Cellenkos

...start in early 2021. Deal terms were undisclosed.United Therapeutics...
...voucher it received via Danyelza naxitamab-gqgk’s approval to United Therapeutics Corp....
...Other), Jakafi (Other) CLN-081 (TAS6417) UB-612 Incyte Corp. Cellenkos Inc. Cullinan Management Inc. United Therapeutics Corp. Y-mAbs...
BioCentury | Jun 4, 2020
Finance

Everest to fund late-stage trials with $310M mountain of fresh cash

...Pharmaceuticals Inc. (NASDAQ:ARNA); PGI2 agonist ralinepag XR for pulmonary arterial hypertension, under a deal with United Therapeutics...
BioCentury | May 14, 2020
Emerging Company Profile

Kriya emerges with $80.5M A round, three gene therapies for diabetes and obesity

...Axovant Gene Therapies Ltd. (NASDAQ:AXGT). His co-founders are Vice Chairman Roger Jeffs, former co-CEO of United Therapeutics...
BioCentury | Dec 20, 2019
Product Development

Pharma spinouts: a snapshot of where and how pharmas spin out their assets

...with a $250M series A round in 2017. Celgene, together with Sorrento Therapeutics Inc. (NASDAQ:SRNE), United Therapeutics Corp....
BioCentury | Sep 11, 2019
Company News

Sept. 11 Company Quick Takes: Glaxo to buy Sitari; plus Aimmune, Xeris, Puma and United Therapeutics

...adjuvant therapy for early stage HER2-positive breast cancer. April PDUFA date for PAH therapy Trevyent United Therapeutics Corp....
...Sackler company, Mundipharma International Ltd. (Dublin, Ireland). BioCentury Staff Avalon Ventures Sitari Pharmaceuticals Inc. GlaxoSmithKline plc Xeris Pharmaceuticals Inc. Purdue Pharma L.P. United Therapeutics Corp. Puma...
BioCentury | Jul 26, 2019
Finance

Earnings on deck

...NASDAQ:AMGN) 7/30 Post $3.59 $3.83 -6% Gilead Sciences Inc. (NASDAQ:GILD) 7/30 Post $1.72 $1.91 -10% United Therapeutics Corp....
BioCentury | Jul 1, 2019
Company News

Management Tracks: BioCryst hires its first CBO; plus ObsEva, Veracyte and more

...as CFO. He was EVP and CFO of SteadyMed Therapeutics Inc., which was acquired by United Therapeutics Corp....
BioCentury | Apr 26, 2019
Company News

Amgen, Astellas join list of biopharmas paying for alleged co-pay charity kickbacks

...Pharmaceuticals Inc. (NASDAQ:ALXN), H. Lundbeck A/S (CSE:LUN), Jazz Pharmaceuticals plc (NASDAQ:JAZZ), Pfizer Inc. (NYSE:PFE) and United Therapeutics Corp....
...Alleged Kickbacks to Co-pay Charities" ). Mary Romeo, Staff Writer Alexion Pharmaceuticals Inc. Amgen Inc. Astellas Pharma Inc. H. Lundbeck A/S United Therapeutics Corp. Actelion...
Items per page:
1 - 10 of 621